Liguori A, Pellegrino G, Di Ieso N, Piatto A, Ruggiero P, Scarnera P, Guardascione A
Clin Ter. 1989 Dec 15;131(5):307-14.
15 patients (10 M, 5 F; age 24-55) with paroxysmal supraventricular tachyarrhythmias (onset: 0.5-4 hours; 8 atrial tachycardias, 5 atrial fibrillation, 2 atrial flutter) were treated with 1 mg/kg i.v. propafenone. Propafenone terminated tachyarrhythmias in all patients during or within a few minutes after stopping infusion (mean conversion time: 6.4 min.). No significant changes in the main electrocardiographic parameters (QRS from 67 +/- to 80 +/- 21 msec., n.s.; QTc from 330 +/- 60 to 320 +/- 40 msec, n.s.), nor in blood pressure (from 128/82 +/- 21/10 to 135/83 +/- 11/8 mmHg, n.s.) were observed. No side effects appeared. In conclusion, propafenone proved to be effective and well tolerated in the acute treatment of supraventricular tachyarrhythmias.
15例阵发性室上性快速心律失常患者(10例男性,5例女性;年龄24 - 55岁)(发作时间:0.5 - 4小时;8例房性心动过速,5例心房颤动,2例心房扑动)接受了1mg/kg静脉注射普罗帕酮治疗。普罗帕酮在所有患者停止输注期间或几分钟内终止了快速心律失常(平均转复时间:6.4分钟)。主要心电图参数(QRS波从67±至80±21毫秒,无显著差异;QTc从330±60至320±40毫秒,无显著差异)以及血压(从128/82±21/10至135/83±11/8mmHg,无显著差异)均未出现显著变化。未出现副作用。总之,普罗帕酮在室上性快速心律失常的急性治疗中被证明是有效且耐受性良好的。